Viqualine (INN) (developmental code name PK-5078) is an antidepressant and anxiolytic drug that was never marketed.

[1][2][3] It acts as a potent and selective serotonin releasing agent (SRA) and serotonin reuptake inhibitor (SRI) similarly to para-chloroamphetamine (PCA).

[3][4][5] In addition, viqualine displaces diazepam from the GABAA receptor and produces benzodiazepine-like effects, indicating that it is also a positive allosteric modulator of the benzodiazepine site of the GABAA receptor.

[3][6] The drug has mainly been researched as a potential treatment for alcoholism.

[7][8] This article about an anxiolytic is a stub.